Protection by immunoglobulin dual-affinity retargeting antibodies against dengue virus

Journal of Virology

Volumn 87, Issue 13, 2013, Pages 7747-7753

  Brien, James D ^a   Sukupolvi Petty, Soila ^a   Williams, Katherine L ^b   Lam, Chia Ying Kao ^c   Schmid, Michael A ^b   Johnson, Syd ^c   Harris, Eva ^b   Diamond, Michael S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c Analytical Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPECIFIC ANTIBODY; DENGUE VIRUS ANTIBODY; FC RECEPTOR; IMMUNOGLOBULIN ANTIBODY; IMMUNOGLOBULIN G1; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4E11; MONOCLONAL ANTIBODY E60; NEUTRALIZING ANTIBODY; RECOMBINANT ANTIBODY; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS PROTEIN;

ANTIBODY AFFINITY; ANTIBODY COMBINING SITE; ANTIBODY SPECIFICITY; ANTIGEN ANTIBODY REACTION; ARTICLE; CELLULAR IMMUNITY; CROSS REACTION; DENGUE; DENGUE VIRUS; DENGUE VIRUS 1; DENGUE VIRUS 2; DENGUE VIRUS 3; DENGUE VIRUS 4; DRUG MECHANISM; DRUG TARGETING; DUAL AFFINITY RETARGETING MOLECULE; HUMAN; MONOTHERAPY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; SEROTYPE; SINGLE DRUG DOSE; TREATMENT RESPONSE; VIRUS NEUTRALIZATION; VIRUS TYPING;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, BISPECIFIC; ANTIBODIES, MONOCLONAL; CROSS REACTIONS; DENGUE; DENGUE VIRUS; EPITOPES; HUMANS; IMMUNOGLOBULIN VARIABLE REGION; KAPLAN-MEIER ESTIMATE; MICE; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MOLECULAR TARGETED THERAPY; NEUTRALIZATION TESTS; SPECIES SPECIFICITY; STATISTICS, NONPARAMETRIC; VIRAL VACCINES;

EID: 84880385914     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.00327-13     Document Type: Article

References (31)

1. Kliks SC, Nimmanitya S, Nisalak A, Burke DS. 1988. Evidence that maternal dengue antibodies are important in the development of dengue hemorrhagic fever in infants. Am. J. Trop. Med. Hyg. 38:411-419.
2. Chau TN, Quyen NT, Thuy TT, Tuan NM, Hoang DM, Dung NT, Lien le B, Quy NT, Hieu NT, Hieu LT, Hien TT, Hung NT, Farrar J, Simmons CP. 2008. Dengue in Vietnamese infants-results of infectionenhancement assays correlate with age-related disease epidemiology, and cellular immune responses correlate with disease severity. J. Infect. Dis. 198:516-524.
3. Mongkolsapaya J, Duangchinda T, Dejnirattisai W, Vasanawathana S, Avirutnan P, Jairungsri A, Khemnu N, Tangthawornchaikul N, Chotiyarnwong P, Sae-Jang K, Koch M, Jones Y, McMichael A, Xu X, Malasit P, Screaton G. 2006. T cell responses in dengue hemorrhagic fever: Are cross-reactive T cells suboptimal? J. Immunol. 176:3821-3829.
4. Zivna I, Green S, Vaughn DW, Kalayanarooj S, Stephens HA, Chandanayingyong D, Nisalak A, Ennis FA, Rothman AL. 2002. T cell responses to an HLA-B*07-restricted epitope on the dengue NS3 protein correlate with disease severity. J. Immunol. 168:5959-5965.
5. Mongkolsapaya J, Dejnirattisai W, Xu XN, Vasanawathana S, Tangthawornchaikul N, Chairunsri A, Sawasdivorn S, Duangchinda T, Dong T, Rowland-Jones S, Yenchitsomanus PT, McMichael A, Malasit P, Screaton G. 2003. Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat. Med. 9:921-927.
6. Pierson TC, Fremont DH, Kuhn RJ, Diamond MS. 2008. Structural insights into the mechanisms of antibody-mediated neutralization of flavivirus infection: implications for vaccine development. Cell Host Microbe 4:229-238.
7. Sukupolvi-Petty S, Austin SK, Purtha WE, Oliphant T, Nybakken G, Schlesinger JJ, Roehrig JT, Gromowski GD, Barrett AD, Fremont DH, Diamond MS. 2007. Typeand subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J. Virol. 81:12816-12826.
8. Shrestha B, Brien JD, Sukupolvi-Petty S, Austin SK, Edeling MA, Kim T, O'Brien KM, Nelson CA, Johnson S, Fremont DH, Diamond MS. 2010. The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1.x 6:e1000823. doi:10.1371/journal.ppat.1000823.
9. Gromowski GD, Barrett AD. 2007. Characterization of an antigenic site that contains a dominant, type-specific neutralization determinant on the envelope protein domain III (ED3) of dengue 2 virus. Virology 366:349-360.
10. Teoh EP, Kukkaro P, Teo EW, Lim AP, Tan TT, Yip A, Schul W, Aung M, Kostyuchenko V.A, Leo YS, Chan SH, Smith KG, Chan AH, Zou G, Ooi EE, Kemeny DM, Tan GK, Ng JK, Ng ML, Alonso S, Fisher D, Shi PY, Hanson BJ, Lok SM, MacAry PA. 2012. The structural basis for serotype-specific neutralization of dengue virus by a human antibody. Sci. Transl. Med. 4:139ra183. doi:10.1126/scitranslmed.3003888.
11. de Alwis R, Beltramello M, Messer WB, Sukupolvi-Petty S, Wahala WM, Kraus A, Olivarez NP, Pham Q, Brien JD, Tsai WY, Wang WK, Halstead S, Kliks S, Diamond MS, Baric R, Lanzavecchia A, Sallusto F, de Silva AM. 2011. In-depth analysis of the antibody response of individuals exposed to primary dengue virus infection. PLoS Negl. Trop. Dis. 5:e1188. doi:10.1371/journal.pntd.0001188.
12. Lok SM, Kostyuchenko V, Nybakken GE, Holdaway HA, Battisti AJ, Sukupolvi-Petty S, Sedlak D, Fremont DH, Chipman PR, Roehrig JT, Diamond MS, Kuhn RJ, Rossmann MG. 2008. Binding of a neutralizing antibody to dengue virus alters the arrangement of surface glycoproteins. Nat. Struct. Mol. Biol. 15:312-317.
13. Gromowski GD, Barrett ND, Barrett AD. 2008. Characterization of dengue virus complex-specific neutralizing epitopes on envelope protein domain III of dengue 2 virus. J. Virol. 82:8828-8837.
14. Rajamanonmani R, Nkenfou C, Clancy P, Yau YH, Shochat SG, Sukupolvi-Petty S, Schul W, Diamond MS, Vasudevan SG, Lescar J. 2009. On a mouse monoclonal antibody that neutralizes all four dengue virus serotypes. J. Gen. Virol. 90:799-809.
15. Thullier P, Demangel C, Bedouelle H, Megret F, Jouan A, Deubel V, Mazie JC, Lafaye P. 2001. Mapping of a dengue virus neutralizing epitope critical for the infectivity of all serotypes: insight into the neutralization mechanism. J. Gen. Virol. 82:1885-1892.
16. Beltramello M, Williams KL, Simmons CP, Macagno A, Simonelli L, Quyen NT, Sukupolvi-Petty S, Navarro-Sanchez E, Young PR, de Silva AM, Rey FA, Varani L, Whitehead SS, Diamond MS, Harris E, Lanzavecchia A, Sallusto F. 2010. The human immune response to dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8:271-283.
17. Balsitis SJ, Williams KL, Lachica R, Flores D, Kyle JL, Mehlhop E, Johnson S, Diamond MS, Beatty PR, Harris E. 2010. Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog. 6:e1000790. doi:10.1371/journal.ppat.1000790.
18. Williams KL, Sukupolvi-Petty S, Beltramello M, Johnson S, Sallusto F, Lanzavecchia A, Diamond MS, Harris E. 2013. Therapeutic efficacy of antibodies lacking FcgammaR against lethal dengue virus infection is due to neutralizing potency and blocking of enhancing antibodies. PLoS Pathog. 9:e1003157. doi:10.1371/journal.ppat.1003157.
19. Oliphant T, Nybakken G, Engle M, Xu Q, Nelson CA, Sukupolvi-Petty S, Marri A, Lachmi B, Olshevsky U, Fremont DH, Pierson TC, Diamond MS. 2006. Determinants of West Nile virus envelope protein domains I and II antibody recognition and neutralization. J. Virol. 80: 12149-12159.
20. Lisova O, Hardy F, Petit V, Bedouelle H. 2007. Mapping to completeness and transplantation of a group-specific, discontinuous, neutralizing epitope in the envelope protein of dengue virus. J. Gen. Virol. 88:23872397.
21. Cockburn JJ, Navarro Sanchez ME, Fretes N, Urvoas A, Staropoli I, Kikuti CM, Coffey LL, Arenzana Seisdedos F, Bedouelle H, Rey FA. 2012. Mechanism of dengue virus broad cross-neutralization by a monoclonal antibody. Structure 20:303-314.
22. Thullier P, Lafaye P, Megret F, Deubel V, Jouan A, Mazie JC. 1999. A recombinant Fab neutralizes dengue virus in vitro. J. Biotechnol. 69:183190.
23. Megret F, Hugnot JP, Falconar A, Gentry MK, Morens DM, Murray JM, Schlesinger JJ, Wright PJ, Young P, Van Regenmortel MHV, Deubel V. 1992. Use of recombinant fusion proteins and monoclonal antibodies to define linear and discontinuous antigenic sites on the dengue virus envelope glycoprotein. Virology 187:480-491.
24. Zellweger RM, Prestwood TR, Shresta S. 2010. Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe 7:128-139.
25. Goncalvez AP, Engle RE, St Claire M, Purcell RH, Lai CJ. 2007. Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention. Proc. Natl. Acad. Sci. U. S. A. 104:9422-9427.
26. Modis Y, Ogata S, Clements D, Harrison SC. 2003. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc. Natl. Acad. Sci. U. S. A. 100:6986-6991.
27. Dowd KA, Jost CA, Durbin AP, Whitehead SS, Pierson TC. 2011. A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus. PLoS Pathog. 7:e1002111. doi:10.1371 /journal.ppat.1002111.
28. Austin SK, Dowd KA, Shrestha B, Nelson CA, Edeling MA, Johnson S, Pierson TC, Diamond M.S, Fremont DH. 2012. Structural basis of differential neutralization of DENV-1 genotypes by an antibody that recognizes a cryptic epitope. PLoS Pathog. 8:e1002930. doi:10.1371/journal .ppat.1002930.
29. Wahala WM, Donaldson EF, de Alwis R, Accavitti-Loper MA, Baric RS, de Silva AM. 2010. Natural strain variation and antibody neutralization of Dengue serotype 3 viruses. PLoS Pathog. 6:e1000821. doi:10.1371/journal .ppat.1000821.
30. Kuhn RJ, Zhang W, Rossmann MG, Pletnev SV, Corver J, Lenches E, Jones CT, Mukhopadhyay S, Chipman PR, Strauss EG, Baker TS, Strauss JH. 2002. Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108:717-725.
31. Brien JD, Austin SK, Sukupolvi-Petty S, O'Brien KM, Johnson S, Fremont DH, Diamond MS. 2010. Genotype-specific neutralization and protection by antibodies against dengue virus type 3. J. Virol. 84:10630-10643.